非霍奇金淋巴瘤患者的疫苗接种管理
本文综述了非霍奇金淋巴瘤(NHL)患者接种COVID-19及其他疫苗的有效性数据,指出抗CD20单克隆抗体治疗后疫苗诱导的免疫应答显著降低,并提出了多学科团队-based的疫苗接种管理建议。
要点
- NHL患者接种疫苗是预防感染的重要手段,COVID-19大流行提高了对疫苗接种的认识。
- 抗CD20单克隆抗体治疗后疫苗诱导的免疫应答显著降低。
- 本文提出多学科团队-based的NHL患者疫苗接种管理建议。
核心结论
- 抗CD20单克隆抗体治疗后疫苗诱导的免疫应答显著降低,需 refined 免疫策略。
研究设计与样本
- 综述,总结NHL患者中COVID-19及其他疫苗有效性的现有数据。
主要发现
- 多项研究证实抗CD20单克隆抗体治疗后疫苗诱导的免疫应答显著降低。
临床怎么用
- 提出多学科团队-based的NHL患者疫苗接种管理建议。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non-Hodgkin lymphomas (NHLs). The COVID-19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life-threatening SARS-CoV-2-related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine-induced immune responses after anti-CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients. In this review, we summarize the existing data about COVID-19 and other vaccine's efficacy in patients with NHL and propose multidisciplinary team-based recommendations for the management of vaccines in this specific group of patients.
引用
- Merli M, Costantini A, Tafuri S, et al. Management of vaccinations in patients with non-Hodgkin lymphoma. Br J Haematol. 2024. PMID: 38532527. doi:10.1111/bjh.19422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。